BioSpace News Archive

The Texas Cardiac Arrhythmia at St. David’s Healthcare wants to ensure that our testing and treatment of patients is of the highest quality, and the health and safety of our employees and those who come to us for care is our primary concern.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced a change in location of its 2020 Annual Meeting of Stockholders to be held at 9:00 AM PT, on Thursday, June 4, 2020.

CHOP researchers report a 2.5-fold decrease in pediatric fractures overall, due to organized sports cancellations and playground closures

Diaceutics today reveals new data insights into key areas of cancer testing. In collaboration with the company’s network of industry advisors, the research has just been published in four abstracts and one poster at this year’s virtual American Society of Clinical Oncology (ASCO) conference

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of its executive team will participate in a Fireside Chat during the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30pm EDT.

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today reported financial results for the quarter ended March 31, 2020 and provided a corporate update.

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the William Blair 40th Annual Growth Stock Conference on Tuesday, June 9, at 12:00 p.m. C.T.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering

Clovis Oncology Announces New Recommendations for Rubraca ® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines ® for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Rubraca recommended as a treatment option for BRCA-mutant mCRPC in the second line setting and as a subsequent therapy; if the patient is not fit for chemotherapy, rucaparib can be considered prior to taxane

TSRL, Inc., announces the continued development of a transdermal delivery system of zanamivir, an inhalation drug product licensed for the treatment and prevention of influenza A & B.